A recent study showed that treatment with neutralizing antibodies against PD1 and CTLA4 in combination with a FAK inhibitor significantly reduced pancreatic tumor size and increased survival rates in pancreatic cancer mouse models30. This evidence concerns the gene PTK2 and pancreatic neoplasm.